{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T05:31:24Z","timestamp":1771651884386,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jocn.2022.04.035","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T12:56:51Z","timestamp":1651669011000},"page":"32-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Development and validation of a simple and practical method for differentiating MS from other neuroinflammatory disorders based on lesion distribution on brain MRI"],"prefix":"10.1016","volume":"101","author":[{"given":"J.","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pires","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Derman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Fatterpekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.E.","family":"Charlson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Kister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jocn.2022.04.035_b0005","first-page":"89","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat RevNeurol"},{"issue":"1","key":"10.1016\/j.jocn.2022.04.035_b0010","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.jocn.2022.04.035_b0015","unstructured":"Voinov, Nikita. Proceedings of International Scientific Conference on Telecommunications, Computing and Control. Springer Nature."},{"issue":"6","key":"10.1016\/j.jocn.2022.04.035_b0020","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1177\/1352458520966298","article-title":"The emerging role of artificial intelligence in multiple sclerosis imaging","volume":"28","author":"Afzal","year":"2022","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2022.04.035_b0025","doi-asserted-by":"crossref","first-page":"599042","DOI":"10.3389\/fneur.2020.599042","article-title":"Deep Learning-Based Method to Differentiate Neuromyelitis Optica Spectrum Disorder from Multiple Sclerosis","volume":"11","author":"Kim","year":"2020","journal-title":"Front Neurol"},{"issue":"23","key":"10.1016\/j.jocn.2022.04.035_b0030","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1212\/WNL.0000000000003395","article-title":"Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest","volume":"87","author":"Eshaghi","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jocn.2022.04.035_b0035","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/13524585211007086","article-title":"Central vein sign and other radiographic features distinguishing myelin oligodendrocyte glycoprotein antibody disease from multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica","volume":"28","author":"Ciotti","year":"2022","journal-title":"Mult Scler"},{"issue":"11","key":"10.1016\/j.jocn.2022.04.035_b0040","article-title":"Iron Rims as an Imaging Biomarker in Ms: A Systematic Mapping Review","volume":"10","author":"AlTokhis","year":"2020","journal-title":"Diagnostics (Basel, Switzerland)"},{"issue":"8","key":"10.1016\/j.jocn.2022.04.035_b0045","doi-asserted-by":"crossref","DOI":"10.1001\/archneurol.2010.188","article-title":"Interferon Beta Treatment in Neuromyelitis Optica: Increase in Relapses and Aquaporin 4 Antibody Titers","volume":"67","author":"Palace","year":"2010","journal-title":"Archiv Neurol"},{"key":"10.1016\/j.jocn.2022.04.035_b0050","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.msard.2018.09.011","article-title":"Severe disease exacerbation in a patient with neuromyelitis optica spectrum disorder during treatment with dimethyl fumarate","volume":"26","author":"Popiel","year":"2018","journal-title":"Multiple Sclerosis Related Disord"},{"key":"10.1016\/j.jocn.2022.04.035_b0055","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.msard.2016.03.004","article-title":"Fingolimod-induced leukoencephalopathy in a patient with neuromyelitis optica spectrum disorder","volume":"7","author":"Yoshii","year":"2016","journal-title":"Multiple Sclerosis Related Disord"},{"issue":"1-2","key":"10.1016\/j.jocn.2022.04.035_b0060","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jns.2014.01.035","article-title":"Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab","volume":"339","author":"Kitley","year":"2014","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jocn.2022.04.035_b0065","unstructured":"http:\/\/fyra.io. \u201cThe Multiple Sclerosis Lesion Checklist.\u201d Practical Neurology, https:\/\/practicalneurology.com\/articles\/2018-july-aug\/the-multiple-sclerosis-lesion-checklist. Accessed 9 May 2021."},{"issue":"2","key":"10.1016\/j.jocn.2022.04.035_b0070","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.jocn.2022.04.035_b0075","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2022.04.035_b0080","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00960","article-title":"The Expanding Clinical Spectrum of Myelin Oligodendrocyte Glycoprotein (Mog) Antibody Associated Disease in Children and Adults","volume":"11","author":"Parrotta","year":"2020","journal-title":"Front Neurol"},{"issue":"14","key":"10.1016\/j.jocn.2022.04.035_b0085","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1212\/WNL.0b013e3182887957","article-title":"Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution","volume":"80","author":"Matthews","year":"2013","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jocn.2022.04.035_b0090","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/jnnp-2016-314005","article-title":"Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease","volume":"88","author":"Jury\u0144czyk","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.jocn.2022.04.035_b0095","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1177\/1352458518761186","article-title":"Evaluation of brain lesion distribution criteria at disease onset in differentiating MS from NMOSD and MOG-IgG-associated encephalomyelitis","volume":"25","author":"Hyun","year":"2019","journal-title":"Mult Scler"},{"issue":"2","key":"10.1016\/j.jocn.2022.04.035_b0100","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/13524585211018987","article-title":"Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis","volume":"28","author":"Messina","year":"2022","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2022.04.035_b0105","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.neubiorev.2018.02.012","article-title":"The role of the cerebellum in multiple sclerosis\u2014150 years after Charcot","volume":"89","author":"Parmar","year":"2018","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.jocn.2022.04.035_b0110","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.msard.2018.08.008","article-title":"Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis","volume":"25","author":"Bensi","year":"2018","journal-title":"Multiple Sclerosis Related Disord"},{"issue":"8","key":"10.1016\/j.jocn.2022.04.035_b0115","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1177\/1352458519849517","article-title":"Brain and spinal MRI features distinguishing MS from different AQP4 antibody serostatus NMOSD at disease onset in a cohort of Latin American patients","volume":"26","author":"Carnero Contentti","year":"2020","journal-title":"Mult Scler"},{"issue":"14","key":"10.1016\/j.jocn.2022.04.035_b0120","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1177\/1352458519893093","article-title":"MRI differences between MOG antibody disease and AQP4 NMOSD","volume":"26","author":"Salama","year":"2020","journal-title":"Mult Scler"},{"issue":"3","key":"10.1016\/j.jocn.2022.04.035_b0125","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/brain\/aww350","article-title":"Distinct Brain Imaging Characteristics of Autoantibody-Mediated CNS Conditions and Multiple Sclerosis","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586822001941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586822001941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:30:25Z","timestamp":1760823025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586822001941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":25,"alternative-id":["S0967586822001941"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2022.04.035","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of a simple and practical method for differentiating MS from other neuroinflammatory disorders based on lesion distribution on brain MRI","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2022.04.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}